1. American Society of Anaesthesiologists (ASA) class 3 and above. 2. Stage 4 severe chronic kidney disease or requiring dialysis (eGFR < 30) 3. Pregnant or breast feeding. 4. Anticipated transfer to another facility which is not a study site within 72 hours. 5. Participants with known haematological diseases (G6PD deficiency) 6. Participants with chronic liver and kidney disease and reaching end-stage. 7. Participants with arrhythmia and chronic heart disease. 8. Participants known to have retinal disease or hearing loss. 9. Participants known to have a mental illness. 10. Skin disorders (including rash, dermatitis, psoriasis). 11. Allergy to Ivermectin or its analogues.

1. American Society of Anaesthesiologists (ASA) class 3 and above. 2. Stage 4 severe chronic kidney disease or requiring dialysis (eGFR < 30) 3. Pregnant or breast feeding. 4. Anticipated transfer to another facility which is not a study site within 72 hours. 5. Participants with known haematological diseases (G6PD deficiency) 6. Participants with chronic liver and kidney disease and reaching end-stage. 7. Participants with arrhythmia and chronic heart disease. 8. Participants known to have retinal disease or hearing loss. 9. Participants known to have a mental illness. 10. Skin disorders (including rash, dermatitis, psoriasis). 11. Allergy to Ivermectin or its analogues.